

## 20/20 Biolabs and DAISource Announce Development of New Blood Test for Chronic Disease Risk Assessment Solution Built with AI

*Product integrates inflammatory biomarker values with individual eating habits and large body of curated scientific studies to provide personalized dietary individual recommendations for healthier lifestyles*

**Gaithersburg MD – November 4, 2025** -- 20/20 Biolabs and DAISource announced today the development of a new blood test anticipated to be launched early next year, to help people track their levels of chronic inflammation which contributes to several major chronic diseases.

The OneTest for Longevity platform is being designed to combine the lab values of inflammatory and metabolic biomarkers, results from a Food Frequency Questionnaire (FFQ), and thousands of scientific publications to calculate and display an individual's risk of being diagnosed with chronic diseases such as diabetes, dementia, and cardiovascular disease. Using IBM watsonx.ai to integrate and analyze data from the scientific literature numerous sources, together with the resultant lab values and the FFQ\*, the product will offer personalized, evidence-based dietary recommendations to help individuals reduce understand patterns in their biomarker levels and associated disease risks.

"We are excited to partner with DAISource to bring our vision of AI-enabled health solutions to life," said Jonathan Cohen, CEO of 20/20 Biolabs. "This collaboration enables us to leverage DAISource's expertise in integrating advanced AI capabilities from IBM to develop a robust and scalable solution that can make a significant impact on public health."

"Our collaboration with 20/20 Biolabs represents a significant step forward in bringing AI capabilities to healthcare applications," said William DeSpain, President at DAISource. "By integrating IBM's technological capabilities with 20/20 Biolabs' innovative approach to disease prevention, we aim to deliver a solution that makes health analysis faster and more efficient for individuals worldwide."

The OneTest for Longevity platform leverages IBM watsonx.ai's enterprise AI capabilities, integrated by DAISource, to analyze patient biomarker data, dietary habits, and thousands of peer-reviewed publications to inform scientifically-grounded, personalized nutritional recommendations. IBM's ISO 42001-certified Granite 4.0 foundation models provide the advanced reasoning capabilities essential for healthcare solutions, while the open-source Docling toolkit processes complex nutritional research 30 times faster than traditional methods, extracting precise data on food-inflammation relationships.

The scientific publications being analyzed by the algorithms are being curated by Dr. James R. Hébert and his team at the University of South Carolina, which developed the Dietary Inflammatory Index™ (DII®), which has been used in thousands of nutritional studies worldwide. He has published over 330 peer-reviewed papers in high-impact medical journals, with most of these focusing on various aspects of diet on health including methodologic issues encountered in the measurement of diet. Dr. Hébert has established strong collaborations around the world in the areas of public health, cancer prevention and control, and epidemiology & biostatistics as a nutritional and cancer epidemiologist. Over the decade, Dr. Hébert has spent considerable effort developing the DII®, which has now been established as an effective research tool and translated to a suite of products to guide individuals on a path to improved health outcomes.

20/20 Biolabs' OneTest has neither sought nor received FDA approval; it is offered as a laboratory-developed test (LDT) in its CLIA-licensed and CAP-accredited labs.

\*IBM is acting as an information technology provider only. IBM does not purport to be engaged in the practice of medicine or any other professional clinical or licensed activity and IBM's offerings are not designed or intended to constitute protocols for delivering medical

care, a substitute for professional medical advice, diagnosis or treatment or judgement, a drug, drug-adjunct technology, or drug development tool subject to quality system requirements, or medical device as defined under the laws of any jurisdiction.

### **About 20/20 Biolabs**

20/20 Biolabs is a Maryland based organization that pioneers innovative bio-testing and cancer diagnostic tools that address compelling unmet needs. 20/20's digital diagnostics business develops and commercializes A.I. powered cancer screenings tests, delivering better tools to improve early detection of the most common cancers globally.

### **About DAISource**

DAI Source, IBM Platinum Business Partner, is a noted technology and solutions firm based in Irving, Texas providing consulting services in Data Management, Analytics and Security Solutions to a broad range of clients across the U.S.